AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery

Scar formation can cause the failure of glaucoma filtration surgery. We investigated the effect of AR12286, a selective Rho-associated kinase inhibitor, on myofibroblast transdifferentiation and intraocular pressure assessment in rabbit glaucoma filtration surgery models. Cell migration and collagen contraction were used to demonstrate the functionality of AR12286-modulated human conjunctival fibroblasts (HConFs). Polymerase chain reaction quantitative analysis was used to determine the effect of AR12286 on the production of collagen Type 1A1 and fibronectin 1. Cell migration and collagen contraction in HConFs were activated by TGF-&beta
1. However, compared with the control group, rabbit models treated with AR12286 exhibited higher reduction in intraocular pressure after filtration surgery, and decreased collagen levels at the wound site in vivo. Therefore, increased &alpha
SMA expression in HConFs induced by TGF-&beta
1 could be inhibited by AR12286, and the production of Type 1A1 collagen and fibronectin 1 in TGF-&beta
1-treated HConFs was inhibited by AR12286. Overall, the stimulation of HConFs by TGF-&beta
1 was alleviated by AR12286, and this effect was mediated by the downregulation of TGF-&beta
receptor-related SMAD signaling pathways. In vivo results indicated that AR12286 thus improves the outcome of filtration surgery as a result of its antifibrotic action in the bleb tissue because AR12286 inhibited the TGF-&beta
receptor-related signaling pathway, suppressing several downstream reactions in myofibroblast transdifferentiation.